1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
| Autor: | Eggermont, A.M.M., Kicinski, M., Blank, C.U., Mandalà, M., Long, G.V., Atkinson, V.G., Dalle, S., Haydon, A.M., Meshcheryakov, A., Khattak, M.A., Carlino, M.S., Sandhu, S.K., Puig Sarda, S., Ascierto, P.A., Lorigan, P., Grebennik, D., Krepler, C., Marreaud, S.I., Suciu, S., Robert, C. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S725-S726 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|